Harlan Robins - Adaptive Biotechnologies Co-Founder, Chief Scientific Officer


USD 6.61  0.09  1.38%   

Dr. Harlan Robins is a CoFounder, Chief Scientific Officerof the Company.Dr. Robins leads our scientific research and development teams. He is also currently an Associate Faculty Member of the Fred Hutchinson Cancer Research Center . Dr. Robins background in science is remarkable. He obtained his bachelors degree at Harvard University as a physics major with a concentration in mathematics. He then obtained his Masters and Ph.D. in theoretical physics from the University of California Berkeley Science in Israel. Interested in the mathematics behind genetics and observing the potential utility of highlevel mathematics to study problems in the biological sciences, Dr. Robins took another postdoctoral appointment at the Institute for Advance Study in Princeton to study under the famed biologist Dr. Arnold Levine. Working with Dr. Levine, Dr. Robins concentrated on developing bioinformatic algorithms for micro RNA targets and bacterial genome analysis, a precursor to his current faculty appointment at the Fred Hutchinson Cancer Research Center in the Computational Biology Group, Public Health Sciences and Human Biology Divisions. In 2009, Dr. Robins was the recipient of the Ellison Award from the Ellison Medical Foundation New Scholars Program to support new investigators of outstanding promise in the basic biological sciences
206 659 0067  https://www.adaptivebiotech.com
Robins was also granted the Keck Foundation Medical Research Award in 2010, along with Dr. Christopher Carlson, to support their work at the FHCRC in advanced DNA sequencing methods to measure past and present pathogenic exposure in humans.

Harlan Robins Latest Insider Activity

Tracking and analyzing the buying and selling activities of Harlan Robins against Adaptive Biotechnologies stock is an integral part of due diligence when investing in Adaptive Biotechnologies. Harlan Robins insider activity provides valuable insight into whether Adaptive Biotechnologies is net buyers or sellers over its current business cycle. Note, Adaptive Biotechnologies insiders must abide by specific rules, including filing SEC forms every time they buy or sell Adaptive Biotechnologies'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Adaptive Biotechnologies Management Efficiency

Adaptive Biotechnologies has return on total asset (ROA) of (14.94) % which means that it has lost $14.94 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (35.88) %, meaning that it created substantial loss on money invested by shareholders. Adaptive Biotechnologies management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 113.52 M in liabilities with Debt to Equity (D/E) ratio of 0.21, which may suggest the company is not taking enough advantage from borrowing. Adaptive Biotechnologies has a current ratio of 3.57, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Adaptive Biotechnologies until it has trouble settling it off, either with new capital or with free cash flow. So, Adaptive Biotechnologies' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Adaptive Biotechnologies sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Adaptive to invest in growth at high rates of return. When we think about Adaptive Biotechnologies' use of debt, we should always consider it together with cash and equity.
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington. Adaptive Biotechnologies operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 858 people. Adaptive Biotechnologies Corp (ADPT) is traded on NASDAQ Exchange in USA and employs 858 people.

Adaptive Biotechnologies Leadership Team

Elected by the shareholders, the Adaptive Biotechnologies' board of directors comprises two types of representatives: Adaptive Biotechnologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Adaptive. The board's role is to monitor Adaptive Biotechnologies' management team and ensure that shareholders' interests are well served. Adaptive Biotechnologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Adaptive Biotechnologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
Jeffery Vender, Independent Director
Steven Napolitano, Independent Director
Ronald Taylor, Independent Director
Harlan Robins, Co-Founder, Chief Scientific Officer
Ricardo Martinez, Chief Medical Officer
Dean Schorno, CFO
Nancy Hill, Senior Vice President General Manager - Research Products
Daniel Rosenberg, Director
James Muzzarelli, Executive Medical Director
Frank Williams, CFO, Executive Vice President
Stephen Mengert, Director
Richard Covert, Chairman of the Board
Gregory Scott, Independent Director
Chad Robins, President CEO, Co-Founder
Willis, Senior Vice President General Manager - Diagnostic Products
Andrew Jordan, Chief Marketing Officer
Timothy Fielding, CFO and Treasurer
Graham Cherrington, Pres and COO
Traci Bowen, Sr. VP of HR
Thomas Hall, Chairman and CEO

Adaptive Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Adaptive Biotechnologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Adaptive Biotechnologies without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Transaction History Now


Transaction History

View history of all your transactions and understand their impact on performance
All  Next Launch Module

Pair Trading with Adaptive Biotechnologies

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Adaptive Biotechnologies position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Adaptive Biotechnologies will appreciate offsetting losses from the drop in the long position's value.

Moving together with Adaptive Biotechnologies

+0.68HPQHp Inc Fiscal Year End 22nd of November 2022 PairCorr
The ability to find closely correlated positions to Adaptive Biotechnologies could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Adaptive Biotechnologies when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Adaptive Biotechnologies - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Adaptive Biotechnologies Corp to buy it.
The correlation of Adaptive Biotechnologies is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Adaptive Biotechnologies moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Adaptive Biotechnologies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Adaptive Biotechnologies can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Please continue to Trending Equities. You can also try Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.

Complementary Tools for analysis

When running Adaptive Biotechnologies price analysis, check to measure Adaptive Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptive Biotechnologies is operating at the current time. Most of Adaptive Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adaptive Biotechnologies' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Adaptive Biotechnologies' price. Additionally, you may evaluate how the addition of Adaptive Biotechnologies to your portfolios can decrease your overall portfolio volatility.
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Bond Directory
Find actively traded corporate debentures issued by US companies
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Is Adaptive Biotechnologies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adaptive Biotechnologies. If investors know Adaptive will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adaptive Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Adaptive Biotechnologies is measured differently than its book value, which is the value of Adaptive that is recorded on the company's balance sheet. Investors also form their own opinion of Adaptive Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Adaptive Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adaptive Biotechnologies' market value can be influenced by many factors that don't directly affect Adaptive Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adaptive Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine Adaptive Biotechnologies value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adaptive Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.